Objectives: This study aims to evaluate the predictive value of the Mehran score for contrast-induced nephropathy (CIN) following peripheral transcatheter angioplasty (PTA) in patients with peripheral artery disease (PAD). Patients and methods: Between January 2020 and July 2024, a total of 103 patients (74 males, 29 females; mean age: 62.610.1 years; range, 44 to 75 years) who underwent PTA were retrospectively analyzed. The Mehran score was calculated for all patients meeting inclusion criteria. Contrast-induced nephropathy was defined as an absolute increase in serum creatinine ≥0.5 mg/dL or a relative increase ≥25% within 48 to 72 h post-procedure. The predictive value of the Mehran score was calculated using the receiver operating characteristic (ROC) curve analysis. Multivariate logistic regression identified independent risk factors for CIN. Results: Contrast-induced nephropathy occurred in 19 patients (18.4%). Patients who developed CIN received significantly higher contrast volumes (p<0.05). The optimal Mehran score cut-off for predicting CIN was 11.2, with an area under the curve (AUC) of 0.712 (95% confidence interval [CI]: 0.612-0.826; sensitivity 69%, specificity 73%). Independent predictors of CIN included advanced age, diabetes mellitus, higher contrast volume, baseline glomerular filtration rate, and the Mehran score. Patients with CIN had longer hospital stays (3.91.7 vs. 1.90.7 days, p=0.002) and higher amputation rates (10.6% vs. 2.9%, p=0.004). Conclusion: The Mehran score is a valuable tool for predicting CIN after PTA in PAD patients. Risk stratification using the Mehran score may guide preventive strategies, although PAD-specific models incorporating additional parameters are warranted.
